Tag: AACR
José Baselga, a Leading Cancer Researcher, Dies at 61
José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...
AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize...
Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression...
AACR 2020: Phase I Clinical Trial with STRO-002 Shows Encouraging...
Updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from an on-going Phase I dose-escalation phase clinical...
Growing Number of Major Medical Meetings Cancelled – AACR and Others...
The novel coronavirus, also known as COVID19, is prompting major medical societies and healthcare organizations to cancel conferences and events around the world.
The decision...
15th ICML ADC Presentation Overview
The International Conference on Malignant Lymphoma (ICML), which will be held June 18-22, 2019 in the Palazzo dei Congressi, Lugano, Switzerland and is organized...
Mersana Presents Updated Data about its Dolasynthen Platform and Synthemer Scaffold
Clinical-stage bio-pharmaceutical company, Mersana Therapeutics, presented preclinical data from the company's proprietary Dolasynthen platform and its modular Synthemer scaffold during the 2019 Annual Meeting...
How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s...
In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month of his failure to disclose...
Eric Rosenthal Reports | A Personal Remembrance of Two Giants of...
James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the age of 92 on March...
Preclinical Data Supports the Development of XMT-1536 in a Broad Population...
Update data from preclinical studies with XMT-1536, an antibody-drug conjugates or ADC being developed by Mersana Therapeutics targeting NaPi2b, were presented in a poster...
AACR 2017: Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology
Multiple data presentations supporting Seattle Genetics' advancing antibody-drug conjugate or ADC and immuno-oncology programs were presented at the Annual Meeting of the American Association...
